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Abstract
Purpose: The delivery of post-mastectomy radiation therapy (PMRT) can be challenging for patients with left sided
breast cancer that have undergone mastectomy. This study investigates the use of protons for PMRT in selected
patients with unfavorable cardiac anatomy. We also report the first clinical application of protons for these patients.
Methods and materials: Eleven patients were planned with protons, partially wide tangent photon fields (PWTF),
and photon/electron (P/E) fields. Plans were generated with the goal of achieving 95% coverage of target volumes
while maximally sparing cardiac and pulmonary structures. In addition, we report on two patients with unfavorable
cardiac anatomy and IMN involvement that were treated with a mix of proton and standard radiation.
Results: PWTF, P/E, and proton plans were generated and compared. Reasonable target volume coverage was
achieved with PWTF and P/E fields, but proton therapy achieved superior coverage with a more homogeneous
plan. Substantial cardiac and pulmonary sparing was achieved with proton therapy as compared to PWTF and P/E.
In the two clinical cases, the delivery of proton radiation with a 7.2 to 9 Gy photon and electron component was
feasible and well tolerated. Akimbo positioning was necessary for gantry clearance for one patient; the other was
treated on a breast board with standard positioning (arms above her head). LAO field arrangement was used for
both patients. Erythema and fatigue were the only noted side effects.
Conclusions: Proton RT enables delivery of radiation to the chest wall and regional lymphatics, including the IMN,
without compromise of coverage and with improved sparing of surrounding normal structures. This treatment is
feasible, however, optimal patient set up may vary and field size is limited without multiple fields/matching.
Keywords: Breast cancer, Treatment planning, Proton beam radiation
Introduction
Post-mastectomy radiation therapy (RT) improves dis-
ease free survival (DFS) and overall survival (OS) for lo-
cally advanced breast cancer (LABC) [1]. Unfortunately,
radiation to the chest wall and regional lymphatics car-
ries risks of cardiopulmonary and other toxicities [2]. Al-
though modern techniques minimize high dose radiation
to avoidance structures, some patients with advanced
disease and/or unfavorable anatomy still present a chal-
lenge for radiation planning and compromises in target
coverage or desired sparing of cardiopulmonary struc-
tures is often necessary.
Proton radiation is a form of particle radiation capable
of delivering therapeutic radiation with complete sparing
of tissues beyond the target. Mainly due to patient ca-
pacity limits in the relatively small number of clinical
proton facilities, the clinical use of protons has been li-
mited to tumors requiring high doses or to those in
close proximity to critical structures (e.g. brain, spinal
cord). Despite substantial capital and operational costs,
several proton facilities have recently opened or are in
planning or construction phases. Furthermore, several
companies are actively researching more efficient,
smaller, and less expensive equipment for proton therapy
* Correspondence: smacdonald@partners.org
Department of Radiation Oncology, Massachusetts General Hospital, Harvard
Medical School, Cox 340, 100 Blossom Street, Boston, MA 02114, USA
© 2013 MacDonald et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
MacDonald et al. Radiation Oncology 2013, 8:71
http://www.ro-journal.com/content/8/1/71delivery. Given the increasing availability of proton ra-
diation in both academic and private sectors, it is critical
to evaluate potential benefits and techniques for the
treatment of additional malignancies, such as breast can-
cer, for which the defined range of the proton might re-
duce normal tissue radiation dose, allow concurrent
chemotherapy or some combination thereof for an im-
provement in patient outcome. Comparative planning
studies hypothesize that protons will provide a decrease
in acute and late cardiopulmonary toxicities for patients
requiring RT for advanced or left sided breast cancer, but
no clinical experience has been reported to date for this
group of patients [3-5]. We report dosimetric compari-
sons for eleven patients with left sided breast cancer re-
quiring post-mastectomy radiation therapy (PMRT)
planned with 3D CRT, partially wide tangent fields
(PWTF), and a mixed photon electron (P/E) technique to
compare target coverage and conformality across these
treatment modalities. We also report on the clinical tech-
nique and feasibility for two patients treated with a com-
bination of proton and photon radiation for LABC.
Methods and materials
Dosimetric comparisons
For eleven representative cases, we compared PWTF, mi-
xed P/E technique, and 3D-conformal, passively scattered
proton beam radiation. Plans were performed with the
attempt to achieve 95% coverage of target volumes (chest
wall, internal mammary lymph nodes (IMN), supracla-
vicular lymph nodes (SCV), and axilla) while maximally
sparing cardiac and pulmonary structures. Four patients
were planned for treatment to the chest wall and IMN
only. Seven were planned for chest wall, IMN, SCV, and
axillary apex or full axilla. Priority was given to target vol-
ume coverage. Field-in-field technique was used in PWTF
and P/E plans to minimize hot spots. Compromise of tar-
get coverage was not allowed to minimize hot spots or
spare cardiopulmonary structures. Standard proton plan-
ning was performed with XiO planning software (CMS
Inc., St Louis, Missouri). The XXX Proton Therapy Center
provides a rotational gantry system and maximum proton
beam energy of 235-MeV. The CTV prescription for all
dosimetric comparisons was 50 Gy (RBE).
Patients
Two women with locally advanced/inflammatory breast
cancer were referred to the Francis H. Burr Proton Faci-
lity for proton radiation after difficulty in radiation plan-
ning with conventional techniques. Dedicated planning
with Computed Tomography (CT) scans was obtained.
Patients were immobilized, with a custom Civco
™ breast
board in the supine position, one with left arm akimbo
Table 1 Average volumes (%) of critical organs and targets at specific dose levels (Gy RBE) for the three treatment
techniques, PWTF, P/E, and 3D CPT, with the range of values shown in parentheses
Vol (%) Dose levels PWTF P/E 3D CPT
Heart V5Gy 20.9 (14.1–29.2) 35.6 (28.6–45.7) 4.1 (2.6–7.6)
V10Gy 14.9 (8.9–21.9) 22.7 (15.2–31.8) 2.8 (1.6–6.1)
V20Gy 12.0 (6.6–18.4) 12.4 (6.3–18.9) 1.6 (0.6–4.5)
V45Gy 6.9 (2.8–12.4) 2.2 (0.1–5.5) 0.3 (0.0–1.6)
Lung V5Gy 33.2 (12.1–50.0) 46.3 (28.1–70.4) 25.2 (9.8–36.2)
V10Gy 28.5 (10.0–42.5) 32.2 (17.0–55.7) 21.3 (8.0–31.8)
V20Gy 25.3 (8.7–36.3) 21.7 (11.8–39.5) 16.2 (5.9–25.9)
Chestwall V45Gy 96.6 (92.6–99.4) 94.9 (88.8–99.0) 99.9 (98.7–100.0)
V47.5Gy 93.6 (87.3–97.7) 90.0 (81.6–95.8) 99.6 (98.1–100.0)
IMN V45Gy 98.1 (90.6–100.0) 94.0 (84.3–100.0) 100.0 (99.7–100.0)
V47.5Gy 96.6 (86.5–100.0) 91.8 (80.5–99.7) 99.9 (99.0–100.0)
Level 1 V45Gy 90.4 (69.2–100.0) 93.8 (70.2–100.0) 99.9 (99.7–100.0)
V47.5Gy 85.7 (52.7–100.0) 91.4 (60.5–100.0) 99.6 (98.8–100.0)
Level 2 V45Gy 95.0 (76.3–100.0) 93.5 (81.7–100.0) 100.0 (100.0–100.0)
V47.5Gy 89.9 (56.4–99.8) 90.7 (70.5–100.0) 100.0 (100.0–100.0)
Level 3 V45Gy 97.6 (92.2–100.0) 85.5 (73.5–99.2) 100.0 (99.9–100.0)
V47.5Gy 93.7 (82.2–100.0) 82.4 (71.0–98.5) 96.8 (92.8–100.0)
SCV V45Gy 98.2 (93.1–100.0) 98.6 (97.2–100.0) 98.6 (92.0–100.0)
V47.5Gy 95.9 (91.8–100.0) 95.7 (87.3–100.0) 95.0 (89.0–100.0)
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the gantry and one with both arms above her head. The
chest wall, regional lymphatics (SCV, level 1, 2, 3 axilla,
and IMN), and organs at risk were contoured according
to RTOG guidelines by a radiation oncologist [6]. CTV
was defined as a combined volume of all target struc-
tures. An additional margin of 8 to 10 mm was added
around the CTV to account for both lateral beam pen-
umbra and PTV together. Correspondingly, 3-5 mm was
used for smearing radius in the design of compensators.
Three and half percent of the maximum beam range
was used to account for range uncertainty. Customized
brass apertures and Lucite compensators were fabricated
on-site by computerized milling machines interfaced
with the treatment planning system for each patient.
Daily positioning was achieved based on bony landmarks
with diagnostic quality orthogonal x-rays compared to
Digitally Reconstructed Radiographs (DRRs). A com-
puter program assisted the therapists in making patient
couch shifts as needed with six degrees of freedom to
more exactly align the patients [7].
A dose of 50.4 Gy (RBE) was prescribed, employing
the relative biological effectiveness (RBE) value of 1.1
[8]. One patient received an additional IMN boost of
5.4 Gy (RBE) to deliver a total dose 55.8 Gy (RBE) to
involved IMNs. Field arrangement chosen to minimize
dose to critical structures while maximizing target co-
v e r a g ew a sas i n g l ef i e l dL A Oo rm a t c h e dL A Of i e l d s
(chest wall and “SCV” field). Feathering was employed
at match line.
Results
Of the eleven patients used for dosimetric comparison,
all had undergone mastectomy without breast recon-
struction and had left sided breast cancer. 3D CPT,
PWTF and P/E plans were generated and compared.
All plans attempted to deliver a target dose of 50 Gy
or Gy (RBE) to 95% of the CTV (chest wall and regio-
nal lymphatics; all patients had chest wall and IMN
targeted +/- level 1, 2, 3 axillary lymph nodes, and
SCV) while sparing cardiac and pulmonary structures.
Comparable tumor volume coverage was achieved with
PWTF and P/E fields, but proton therapy achieved su-
perior coverage with a noticeably more homogeneous
plan and decreased maximum % dose or “hot spot”.
(Table 1, Figures 1, 2, & 3). Substantial normal tissue
sparing was seen with the proton therapy as compa-
red to PWTF and P/E (Table 1, Figures 1 & 4). The
volume of heart receiving 20 Gy or Gy (RBE) was
12%, 12.4%, and 1.6% for PWTF, P/E, and 3D CPT,
respectively. The average V20 for ipsilateral lung was
25.3%, 21.7%, and 16.2% respectively for PWTF, P/E,
and 3D-CPT. Figure 5 demonstrates the improved
Figure 1 Axial images at the level of the heart for photon/electron plan (left), partially wide tangent fields (middle), and
protons (right).
Figure 2 Dose volume histograms for chest wall (a) and
internal mammary nodes (b) averaged over the patients for the
three treatment techniques PWTF (dashed), P/E (thin solid) and
3D CPT (thick solid).
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Coverage of the IMN with 95% was easily achieved
with proton plans, but was not easily achieved with
all P/E plans due to the depth of the upper IMN in
some patients (Figure 2).
Of the two patients treated with proton radiation,
technical delivery was feasible and without complica-
tion Four or five of twenty-eight to thirty-one frac-
tions (7.2–9 Gy of 50.4-55.8 Gy (RBE) were delivered
with photon/electron plans for the two patients trea-
ted. The course of radiation was tolerated well. Grade
2 erythema and fatigue were the only noted acute
side effects. Figure 1 depicts skin toxicities during
and up to 1 year after treatment. The two patients did
not experience radiation pneumonitis, dysphagia, rib
fracture, lymphedema, brachial plexopathy, or any un-
anticipated side effect of treatment at 6 months to 1 year
following radiation. Both are without evidence of di-
sease recurrence.
Discussion
Earlier radiation trials reported an increase in morbidity
and mortality due to cardiac disease, predominantly
in patients treated for left sided breast cancer. Some
authors have suggested that increased mortality from is-
chemic heart disease was the reason for the absence of a
survival benefit for these patients [9]. More recent post-
mastectomy studies utilizing modern techniques have
demonstrated survival benefit without increase in car-
diac mortality to date, but longer follow up is necessary.
SPECT and strain echocardiogram results report changes
in cardiac tissue with doses as low as 3 Gy, but whether
or not these early cardiovascular changes can be used as
a surrogate for late cardiac outcomes has not yet been
determined [2,10,11]. The increased use of cardiotoxic
chemotherapy over the past several years adds yet ano-
ther confounding factor to determining the effect of ra-
diation therapy on cardiac outcomes and it is not yet
known how radiation in the setting of these agents with
Figure 3 Dose volume histograms for nodal target volumes, Level I (a), II (b), III (c) and SCV, averaged over the patients for the three
treatment techniques PWTF (dashed), P/E (thin solid) and 3D CPT (thick solid).
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maximal cardiac sparing achieved through proton the-
rapy has the potential to decrease this risk by de-
creasing mean heart dose as well as volume receiving
40 Gy and 25 Gy (Table 1). It is predicted that for
select patients, protons may offer a reduction in late
cardiac morbidity that may ultimately prove to be cost
effective [14]. For some patients, breath hold tech-
niques or the addition of a heart block may provide
adequate sparing of the heart without compromising
chest wall and IMN coverage. For patients that have
lower inner quadrant primary tumors, LVI, or ina-
dequate displacement or the heart with breath hold,
protons may provide an alternative, albeit more expen-
sive, treatment.
Radiation pneumonitis is a sub-acute side effect repor-
ted in approximately 1-5% of patients treated for breast
cancer without concurrent chemotherapy; higher rates
are seen with concurrent Taxol [15]. Delivery of con-
ventional chest wall and regional lymphatic RT may re-
sult in delivery of 20 Gy to 20–40% of the lung. In
addition, pneumonitis rates have been shown to increase
when large volumes of lung receive low dose irradiation
(5 Gy or 10 Gy) in lung cancer patients [16]. Although
the meaning of low dose lung irradiation for patients
with breast cancer is less clear, the use of techniques in-
creasing the total volume of tissue receiving radiation
(e.g. IMRT, electrons) heightens concern for radiation-
induced malignancies, particularly for young women.
Protons are capable of both reducing high doses of ra-
diation and avoiding exposure of uninvolved tissues to
low dose radiation exposure. (Figure 4, & Table 1).
Inclusion of the IMN for LABC remains quite con-
troversial. The majority of PMRT trials demonstrating
benefit included treatment of the IMN [1,17]. In ad-
dition, Whelan, et al recently reported a DFS benefit and
trend in improved OS for women treated to the regional
lymphatics including the IMN on the National Cancer
Institute of Canada (NCIC) MA-20 trial [18]. These data
indicate a benefit for inclusion of the IMN. Also, with
the use of positron emission tomography (PET) and
high-resolution computed tomography (CT) scans, sus-
picious IMN are sometimes detected, obliging inclusion
of the IMN in the radiation field [19]. The rationale for
excluding IMN treatment when delivering PMRT is that
the risks of increased cardiopulmonary toxicity negate
any potential benefit in DFS. Proton therapy allows for
treatment and superior coverage of these sometimes
deep-seated lymph nodes with minimal cardiopulmo-
nary dose perhaps tipping the risk-benefit ratio in favor
of IMN inclusion.
One concern in delivering passively scattered proton
radiation to either the breast or the chest wall is the in-
creased dose to the skin. Delivery of proton radiation
with a small photon or electron component (7.2–9G yo f
50.4 to 55.8 Gy (RBE) was feasible and well tolerated.
Skin toxicity was both acceptable and within the range
of what would be expected for standard treatment. For
PMRT, the skin is considered a target, and bolus or
electrons are often used to increase dose to the skin. In
addition, although cosmesis is an important outcome,
cardiopulmonary sparing and target coverage are the pri-
mary goals of treatment for these women with locally
advanced breast cancer. For these reasons, we believe
that this is an ideal population of patients to explore the
potential benefits and risks of proton radiation specific
to breast cancer.
Another frequently mentioned concern regarding the
use of proton radiation is cost. Although the dosimetry
delivered by proton therapy is clearly superior to that of
standard RT, clearly superior clinical outcomes are also
necessary to justify the higher cost of proton therapy.
Lundkvist et al, performed a cost analysis indicating that
for carefully selected patients, specifically where cardiac
sparing was at issue, proton therapy could be cost-
effective [14]. If the cost of proton therapy eventually
decreases, and patients are carefully selected, proton the-
rapy may prove cost-effective for selected subgroups of
breast cancer patients.
Figure 4 Dose volume histograms for heart (a) and left lung
(b) over the patients for the three treatment techniques PWTF
(dashed), P/E (thin solid) and 3D CPT (thick solid).
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The rationale for the use of proton radiation for the treat-
ment of breast cancer is to decrease late toxicity by re-
ducing the dose delivered to cardiopulmonary structures
without compromising desired target volume coverage.
This study demonstrates the dosimetric advantages of
protons over PWTF and P/E technique for representative
patients with left sided breast cancer requiring PMRT and
reports on the first clinical use of proton radiation for
post-mastectomy patients. We conclude that protons may
be of benefit for a select population of patients with locally
advanced breast cancer. We are now actively accruing pa-
tients to a clinical trial examining the feasibility of protons
for PMRT (without a photon or electron component) in
the setting of complex anatomy due to unfavorable cardiac
anatomy or breast prostheses.
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